相似文献
1
Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.
Paediatr Child Health. 1999 Oct;4(7):474-89.
2
3
Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Pediatrics. 2003 Dec;112(6 Pt 1):1447-52. doi: 10.1542/peds.112.6.1447.
4
Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.
Pediatr Crit Care Med. 2011 Sep;12(5):580-8. doi: 10.1097/PCC.0b013e3182070990.
5
Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Pediatrics. 1999 Sep;104(3 Pt 1):419-27. doi: 10.1542/peds.104.3.419.
6
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics. 1998 Nov;102(5):1211-6. doi: 10.1542/peds.102.5.1211.
7
Palivizumab in the prophylaxis of respiratory syncytial virus infection.
Expert Rev Anti Infect Ther. 2005 Oct;3(5):719-26. doi: 10.1586/14787210.3.5.719.
8
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Cochrane Database Syst Rev. 2014 May 22(5):CD007743. doi: 10.1002/14651858.CD007743.pub5.
9
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Cochrane Database Syst Rev. 2012 Feb 15(2):CD007743. doi: 10.1002/14651858.CD007743.pub3.
10
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
Cochrane Database Syst Rev. 2013 Jun 5(6):CD007743. doi: 10.1002/14651858.CD007743.pub4.
引用本文的文献
1
Clinical research on RSV prevention in children and pregnant women: progress and perspectives.
Front Immunol. 2024 Jan 24;14:1329426. doi: 10.3389/fimmu.2023.1329426. eCollection 2023.
2
The palivizumab patchwork: Variation in guidelines for Respiratory Syncytial Virus prevention across Canadian provinces and territories.
Paediatr Child Health. 2020 Feb 20;26(2):e115-e120. doi: 10.1093/pch/pxz166. eCollection 2021 Apr-May.
3
Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017.
Arch Dis Child. 2021 Feb;106(2):173-179. doi: 10.1136/archdischild-2020-319472. Epub 2020 Aug 28.
4
Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) Recipients.
Vaccines (Basel). 2020 Apr 21;8(2):192. doi: 10.3390/vaccines8020192.
5
Preventing hospitalizations for respiratory syncytial virus infection.
Paediatr Child Health. 2015 Aug-Sep;20(6):321-33. doi: 10.1093/pch/20.6.321.
6
Respiratory syncytial virus infections in infants affected by primary immunodeficiency.
J Immunol Res. 2014;2014:850831. doi: 10.1155/2014/850831. Epub 2014 Jun 25.
7
The real-life effectiveness of palivizumab for reducing hospital admissions for respiratory syncytial virus in infants residing in Nunavut.
Can Respir J. 2014 May-Jun;21(3):185-9. doi: 10.1155/2014/941367. Epub 2013 Dec 23.
8
A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus.
Virol J. 2013 Jan 10;10:19. doi: 10.1186/1743-422X-10-19.
9
Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.
Eur J Pediatr. 2012 May;171(5):833-41. doi: 10.1007/s00431-011-1654-8. Epub 2011 Dec 28.
10
Prevention of respiratory syncytial virus infection.
Paediatr Child Health. 2009 Oct;14(8):521-32. doi: 10.1093/pch/14.8.521.
本文引用的文献
1
Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent?
Paediatr Child Health. 1998 Nov;3(6):402-4. doi: 10.1093/pch/3.6.402.
2
Respiratory syncytial virus immune globulin intravenous.
Paediatr Child Health. 1998 Jan;3(1):11-4. doi: 10.1093/pch/3.1.11.
3
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
Pediatr Infect Dis J. 1999 Mar;18(3):223-31. doi: 10.1097/00006454-199903000-00004.
4
Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.
J Infect Dis. 1998 Dec;178(6):1555-61. doi: 10.1086/314523.
5
Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
Pediatrics. 1998 Nov;102(5):1211-6. doi: 10.1542/peds.102.5.1211.
6
Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group.
J Pediatr. 1998 Oct;133(4):492-9. doi: 10.1016/s0022-3476(98)70056-3.
7
Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
Pediatr Infect Dis J. 1998 Sep;17(9):787-91. doi: 10.1097/00006454-199809000-00007.
8
9
Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants.
Pediatr Infect Dis J. 1998 Jul;17(7):587-93. doi: 10.1097/00006454-199807000-00003.
10
A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization.
Arch Pediatr Adolesc Med. 1998 Apr;152(4):358-66. doi: 10.1001/archpedi.152.4.358.
Zotero 插件